| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sebastian Walther, Helge Horn, Nadja Razavi, Philipp Koschorke, Alexander Wopfner, Thomas J Müller, Werner Stri. Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone. Journal of clinical psychopharmacology. vol 30. issue 2. 2011-02-16. PMID:20520292. |
we present actigraphic data of 16 schizophrenia patients treated with olanzapine (mean dose, 21.1 mg/d) and 23 with risperidone (mean dose, 4.7 mg/d) to investigate possible differences in their effects on motor activity. |
2011-02-16 |
2023-08-12 |
human |
| Oleksandr Napryeyenko, Benjaminas Burba, Guadalupe Martinez, Nikolay G Neznanov, Tsvi Fischel, Franck J Baylé, Giulio Corrivetti, Enrico Smeraldi, Jonathan Rabinowitz, Andreas Schreine. Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. Journal of clinical psychopharmacology. vol 30. issue 2. 2011-02-16. PMID:20520297. |
risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. |
2011-02-16 |
2023-08-12 |
Not clear |
| Wolfgang Gaebel, Andreas Schreiner, Paul Bergmans, Rosario de Arce, Frédéric Rouillon, Joachim Cordes, Lars Eriksson, Enrico Smerald. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 12. 2011-02-16. PMID:20686456. |
relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. |
2011-02-16 |
2023-08-12 |
Not clear |
| Wolfgang Gaebel, Andreas Schreiner, Paul Bergmans, Rosario de Arce, Frédéric Rouillon, Joachim Cordes, Lars Eriksson, Enrico Smerald. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 35. issue 12. 2011-02-16. PMID:20686456. |
an open-label, randomized, active-controlled, 2-year trial evaluated 710 patients with schizophrenia or related disorders who were switched from stable treatment with oral risperidone, olanzapine, or conventional neuroleptics to risperidone long-acting injectable (rlai) or oral quetiapine. |
2011-02-16 |
2023-08-12 |
Not clear |
| Yasushi Sato, Norio Yasui-Furukori, Hanako Furukori, Manabu Saito, Taku Nakagami, Sunao Kanek. A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients. Experimental and clinical psychopharmacology. vol 18. issue 5. 2011-02-01. PMID:20939648. |
a 75-g oral glucose tolerance test (ogtt) was performed in 22 mildly obese, diabetes-free, japanese patients with schizophrenia who received risperidone or olanzapine for at least 2 months. |
2011-02-01 |
2023-08-12 |
Not clear |
| C W Ritchie, S Harrigan, M Mastwyk, S Macfarlane, N Cheesman, D Ame. Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration. International journal of geriatric psychiatry. vol 25. issue 4. 2011-01-21. PMID:19946860. |
predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration. |
2011-01-21 |
2023-08-12 |
Not clear |
| Monica M Marcus, Charlotte Wiker, Olivia Frånberg, Asa Konradsson-Geuken, Xavier Langlois, Kent Jardemark, Torgny H Svensso. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. The international journal of neuropsychopharmacology. vol 13. issue 7. 2011-01-10. PMID:19835668. |
these data propose that the therapeutic effect of risperidone in schizophrenia can be enhanced and its eps liability reduced by adjunctive treatment with an alpha2-adrenoceptor antagonist, and generally support the notion that the potent alpha2-adrenoceptor antagonistic action of clozapine may be highly important for its unique efficacy in schizophrenia. |
2011-01-10 |
2023-08-12 |
rat |
| Chen-Lin Chang, Dong-Sheng Tzeng, For-Wey Lun. Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. Psychiatry research. vol 180. issue 1. 2011-01-04. PMID:20488552. |
treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. |
2011-01-04 |
2023-08-12 |
Not clear |
| Chen-Lin Chang, Dong-Sheng Tzeng, For-Wey Lun. Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. Psychiatry research. vol 180. issue 1. 2011-01-04. PMID:20488552. |
this study investigated the variables related to the effectiveness and adherence to treatment with risperidone long-acting injection (rlai) in patients with schizophrenia. |
2011-01-04 |
2023-08-12 |
Not clear |
| Hua-Lin Cai, Rong-Hua Zhu, Huan-De Li, Xiang-Hui Zhang, Li Hu, Wen Yang, Hai-Sen Y. Elevated plasma γ-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 34. issue 7. 2010-12-29. PMID:20637820. |
elevated plasma γ-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia. |
2010-12-29 |
2023-08-12 |
Not clear |
| T Ponto, N I Ismail, A B Abdul Majeed, N H Marmaya, Z A Zakari. A prospective study on the pattern of medication use for schizophrenia in the outpatient pharmacy department, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia. Methods and findings in experimental and clinical pharmacology. vol 32. issue 6. 2010-12-16. PMID:20852752. |
nearly 32% of the schizophrenia patients were prescribed with atypical antipsychotics such as olanzapine (10.8%), risperidone (10.0%), quetiapine (7.6%) and clozapine (3.2%). |
2010-12-16 |
2023-08-12 |
Not clear |
| b' Nikolina Jovanovi\\xc4\\x87, Nada Bo\\xc5\\xbeina, Mila Lovri\\xc4\\x87, Vesna Medved, Miro Jakovljevi\\xc4\\x87, Alma Mihaljevi\\xc4\\x87 Pele\\xc5\\xa. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-na\\xc3\\xafve patients with first-episode schizophrenia treated with risperidone. European journal of clinical pharmacology. vol 66. issue 11. 2010-12-15. PMID:20563569.' |
the role of cyp2d6 and abcb1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. |
2010-12-15 |
2023-08-12 |
Not clear |
| Marja Hensen, Bart Heeg, Mickael Löthgren, Ben van Hou. Cost effectiveness of long-acting risperidone in Sweden. Applied health economics and health policy. vol 8. issue 5. 2010-12-10. PMID:20804225. |
in sweden, risperidone long-acting injectable (rlai) is generally used in a population of schizophrenia patients who are at a high risk of being non-compliant. |
2010-12-10 |
2023-08-12 |
Not clear |
| Subramoniam Madhusoodanan, Deval Zaver. Paliperidone use in the elderly. Current drug safety. vol 5. issue 2. 2010-12-07. PMID:20406162. |
paliperidone, the active metabolite of risperidone is a relatively recent introduction for the treatment of schizophrenia. |
2010-12-07 |
2023-08-12 |
Not clear |
| Roger S McIntyre, Lael Cragin, Sonja Sorensen, Huseyin Naci, Tim Baker, Jean-Pascal Rouss. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. Journal of evaluation in clinical practice. vol 16. issue 4. 2010-12-07. PMID:20545800. |
comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in canada: a cost-effectiveness analysis. |
2010-12-07 |
2023-08-12 |
Not clear |
| Roger S McIntyre, Lael Cragin, Sonja Sorensen, Huseyin Naci, Tim Baker, Jean-Pascal Rouss. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. Journal of evaluation in clinical practice. vol 16. issue 4. 2010-12-07. PMID:20545800. |
this study evaluates the cost-effectiveness of four second-generation antipsychotic agents used in canada for the treatment of schizophrenia (ziprasidone, olanzapine, quetiapine, risperidone) with a focus on their long-term metabolic consequences. |
2010-12-07 |
2023-08-12 |
Not clear |
| Igor Locatelli, Matej Kastelic, Jure Koprivsek, Blanka Kores-Plesnicar, Ales Mrhar, Vita Dolzan, Iztok Grabna. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. vol 41. issue 2. 2010-12-02. PMID:20599499. |
a population pharmacokinetic evaluation of the influence of cyp2d6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. |
2010-12-02 |
2023-08-12 |
Not clear |
| Igor Locatelli, Matej Kastelic, Jure Koprivsek, Blanka Kores-Plesnicar, Ales Mrhar, Vita Dolzan, Iztok Grabna. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. vol 41. issue 2. 2010-12-02. PMID:20599499. |
the results of this study imply the potential role of cyp2d6 genotyping in personalizing risperidone therapy in patients with schizophrenia to reduce the incidence of adverse extrapyramidal symptoms. |
2010-12-02 |
2023-08-12 |
Not clear |
| Maria Rosaria A Muscatello, Antonio Bruno, Gianluca Pandolfo, Umberto Micò, Salvatore Settineri, Rocco Zoccal. Emerging treatments in the management of schizophrenia - focus on sertindole. Drug design, development and therapy. vol 4. 2010-11-22. PMID:20856845. |
in controlled clinical trials sertindole was more effective than placebo in reducing positive and negative symptoms, whereas it was as effective as haloperidol and risperidone against the positive symptoms of schizophrenia. |
2010-11-22 |
2023-08-12 |
Not clear |
| Zhen-hua Chen, Gao-hua Wang, Xiao-ping Wang, Yun-xiang Huo, Ming-hua Yang, Li Li, Hong-bing Me. Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial. Clinical rehabilitation. vol 23. issue 11. 2010-11-15. PMID:19786416. |
effect of warm-supplementing kidney yang (wsky) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial. |
2010-11-15 |
2023-08-12 |
Not clear |